IFN-γ is one of the effector factors secreted by activated CD8+ T cells and exerts its function by binding to IFNγR on cancer cells. STATs and interferon regulatory factors (IRF) family are mainly downstream genes of IFN-γ (52). In CD8+ T cell-induced cancer cell ferroptosis, IFN-γ regulates the phosphorylation of STATs (P- STATs) and changes the transcriptional activation of target genes. P-STATs mediate the expression of IRF1 and IRF8 in cancer cells (53, 54), which act as the transcriptional activation factors of ACSL4 and the transcriptional inhibitory factors of P53, respectively, to participate in the induction of cancer cell ferroptosis (36, 55). The low expression of IRF8 in hepatocellular carcinoma and breast cancer has been associated with a low response to immune therapy (IFN-γ and ICIs). In addition, IFN-γ is involved in mitochondrial damage and cell cycle arrest, further promoting cancer cell ferroptosis.

With the action of IFN-γ, the activation of JAK1/2 and phosphorylation of STAT1 increase the expression of IRF1 on cancer cells. IRF1 acts as a transcriptional activation factor on the ACSL4 promoter. ACSL4 is a key enzyme for fatty acid oxidation and reshapes the lipid spectrum in cancer cells under the action of arachidonic acid (AA), increasing lipid peroxidation levels and ferroptosis. Therefore, IFN-γ combined with AA is thought as the endogenous triggering factor for ACSL4-mediated cancer cell ferroptosis, and immune checkpoint inhibitors (ICIs) can significantly enhance the anti-tumor effect (36). Interestingly, recent studies have shown that the accumulation of lipid peroxides induces the activation of PKCβII in cancer cells, and PKCβII can also interact with the Thr328 site of ACSL4 to activate ACSL4. Therefore, the combined use of IFN-γ and fatty acids may promote the rapid amplification of lipid peroxides through positive feedback between PKCβII and ACSL4, reaching a lethal level of cancer cell ferroptosis and enhancing the ability of IFN-γ to induce ferroptosis (56). In another study, Wang et al. found that IFN-γ-mediated P-STAT1 can directly bind to the promoter region to inhibit the expression of SLC7A11 and increase significantly intracellular GSH depletion, lipid peroxidation, and ferroptosis in cancer (37). Consistent with the above studies, Kong et al. verified that IFN-γ treatment induces cancer cell ferroptosis through the STAT1/IRF1/ACSL4 axis in hepatocellular carcinoma. In addition, they found that IFN-γ increases the phosphorylation of STAT3 and inhibits the transcription of SLC7A11, further reducing cystine uptake, and disrupting intracellular redox balance. They also found that the combination of IFN-γ and Erastin enhances mitochondrial oxidation and the loss of mitochondrial membrane potential (MMP), further triggering ferroptosis. Moreover, the combination of IFN-γ and ferroptosis inducers can inhibit the expression of CyclinD1, CDK4, and CDK6 to mediate more cell cycle arrest (39). It has been reported that phosphorylated STAT5 can also bind to the promoter region of SLC7A11 to inhibit its expression, participating in cystine deprivation and disrupting intracellular redox balance, which may trigger ferroptosis (57). IRF8 is another target gene of IFN-γ. Poschel et al. found that the expression level of IRF8 is significantly higher in responders to nivolumab (PD-1 inhibitor) treatment in melanoma patients compared to non-responders. IRF8 can inhibit the expression of P53 protein, increase lipid peroxidation, and promote ferroptosis in melanoma cells (55). Similarly, the IFN-γ and ICIs immune therapies signaling pathway is significantly inhibited with low levels of IRF8 in hepatocellular carcinoma and is associated with poor prognosis (58), while high expression of IRF8 in human breast cancer is associated with better response to immune therapy and chemotherapy (59). Whether IRF8 regulated by immune therapy interferes with ferroptosis is worth further investigation.

In summary, activated CD8+ T cells secrete IFN-γ and act on the key targets of cancer cell ferroptosis. This leads to a decrease in the oxidative buffering capacity of GPX4 and other GSH-dependent enzymes. IFN-γ also promotes lipid peroxidation through ACSL4 using fatty acids and results in selective enrichment of PUFAs to induce cells ferroptosis (38). Ferroptosis is usually induced by exogenous chemical molecules, including erastin, RSL3, and Sorafenib. CD8+ T cell-derived IFN-γ is an important component of anti-cancer immunity, and AA exists in plasma and cells, jointly opening the door to endogenous ferroptosis (36).

The Cell Death Naming Committee has defined immunogenic cell death (ICD) as “a regulated form of cell death that is capable of activating adaptive immune responses in immunocompetent hosts of the same genotype” (60). Many studies have shown that various factors are exposed or released during cell death processes such as necrosis, pyroptosis, autophagy, and apoptosis, which present “find me” and “eat me” signals to mediate immune responses. These factors are collectively referred to as damage-associated molecular patterns (DAMPs) (61). Consistent with other death-related ICDs, Ferroptosis, as a novel form of programmed cell death, can also release DAMPs such as HMGB1, calreticulin, ATP, HSP70, and HSP90 during the death process. These factors are often simultaneously released by cancer cells and act as immune adjuvants to attract and stimulate antigen-presenting cells (APCs). The activated APCs can engulf and process tumor-associated antigens. This ultimately leads to the clonal expansion of tumor-specific CD8+ T cells and elicit an immune response. However, inconsistent with other ICDs, ferroptosis can also inhibit the activation of CD8 T cells due to lipids peroxidation, which causes lipid droplet accumulation and loss of antigen function after APCs engulf ferroptosis corpses ( Table 1 ).

High mobility group box 1 (HMGB1) is a non-histone nuclear protein that has different functions depending on its subcellular localization. Extracellular HMGB1 regulates immune responses by binding to immune cell receptors (70, 71). In various diseases, HMGB1 acts as a redox protein that increases the accumulation of reactive oxygen species (ROS). ROS is considered a stress factor for ferroptosis, and the migration and release of HMGB1 are associated with ROS. Therefore, HMGB1 is often released during ferroptosis and participates in the regulation of CD8+ T cells as tumor antigens (72–77). Song et al. found that overexpression of OTUD1 inhibits the ubiquitination and degradation of iron-responsive element-binding protein 2 (IREB2) in colorectal cancer cells. IREB2, as an iron sensor, participates in the regulation of iron transport proteins and promotes iron uptake and ferroptosis in cancer cells, which significantly increases the release of HMGB1 in the tumor stroma and promotes the CD8+ T cells infiltration in cancer (62). In addition, Efimova et al. treated fibrosarcoma cells and glioblastoma cells with RSL3 and detected the immunogenic characteristics of ferroptosis cells at different time points. The release of HMGB1 reached its maximum level only in the late stage of ferroptosis (24h). The level of HMGB1 in the supernatant of early-stage ferroptotic cells (3h) showed no statistically significant difference compared to that in surviving cancer cells. However, when fibrosarcoma cells and glioblastoma cells were co-cultured with bone marrow-derived dendritic cells (BMDCs), the level of HMGB1 reached its maximum value in the early stage (3h). Whether BMDCs alter the spatiotemporal release of HMGB1 from ferroptotic cells is still unclear. However, early-stage ferroptotic cells can induce BMDCs maturation and active CD8+ T cells to suppress tumor growth by involving. Late-stage ferroptosis cells, on the other hand, can be cleared, but lack immunogenic characteristics (63).

It is worth noting that the role of HMGB1 in immunity is not solely to promote antigen presentation and activate CD8+ T cells. Some studies have shown that HMGB1 can increase the infiltration of immune suppressive cells to weaken the anti-cancer effects of CD8+ T cells (78). Conche et al. found that GPX4 deficiency induces lipid peroxidation and ferroptosis in hepatocellular carcinoma. During this process, it can recruit CD8+ T cells by increasing the expression of CXCL10 and PD-L1 in cancer cells. However, the increase of HMGB1 during ferroptosis leads to the infiltration of myeloid-derived suppressor cells (MDSCs), which are immune suppressive cells in the TME. Blocking the inhibitory effect of MDSCs on CD8+ T cells through ICIs can enhance the anti-cancer effects. The same treatment did not inhibit tumor growth in mice with colon cancer but reduced liver metastasis, indicating the complexity of ferroptosis-induced immunity in the different TMEs (64).

Adenosine triphosphate (ATP) is an essential nucleotide for metabolism and is released into the TME during cell death through lysosomal secretion and vesicle formation. It binds to immune cell receptors, such as DCs’ P2X7R receptor, to initiate tumor immune responses (79). In contrast to HMGB1, ATP is released by fibrosarcoma and glioma cells after 3 hours of RSL3 treatment, reaching a peak at 6 hours. However, the released ATP is depleted by 24 hours. This suggests that ATP induces DCs maturation and initiates CD8+ T cell immunity in the early stages of ferroptosis, but late-stage ferroptosis cells cannot acquire adaptive immunity. In esophageal cancer, inhibiting SCD1 under radiotherapy prevents the conversion of saturated fatty acids to unsaturated fatty acids, increases intracellular lipid peroxidation and ferroptosis, and activates DCs through recognition and activation of ATP released by cancer cells (65). Shikonin enhances ferroptosis and ATP release in multiple myeloma by inhibiting GOTI and promoting iron phagocytosis, thereby activating adaptive immunity (66).

Calreticulin (CRT) is an endoplasmic reticulum luminal Ca2+ buffering protein that is involved in regulating Ca2+ homeostasis and endoplasmic reticulum Ca2+ capacity (80). The damage of cancer cells triggers the gradual translocation and exposure of CRT as a “find me” signal. APCs, especially immature dendritic cells (DCs), can bind to CRT through the CD91 receptor to increase the activation of tumor-specific naive CD8+ T cells (81–84). Therefore, CRT is an important DAMP in the process of cell death. Cancer cell ferroptosis has also been shown to induce tumor immune responses through the exposure of CRT. Zhao et al. found a significant negative correlation between the expression of GPX4 and calreticulin in HNSCC. Inhibition of GPX4 by RSL3 significantly increased cancer cell ferroptosis, promoted the translocation of CRT to the cell surface, downregulated myeloid-derived suppressor cells and M2-like macrophages, increased the number of CD4+ T cells and CD8+ T cells, improved the immunosuppressive microenvironment of head and neck squamous cell carcinoma (HNSCC), and inhibited tumor progression (67). Similarly, Yu et al. used nanopolymer-mediated intracellular Fenton reaction and oxidative stress in cancer cells, which resulted in the exposure of CRT on ferroptotic cancer cells, leading to DCs maturation and infiltration of cytotoxic T lymphocytes (68).

Other DAMPs Cancer cell death is accompanied by the release of a large number of tumor antigenic molecules. In addition to HMGB1, CRT, and ATP mentioned above, there are many other antigenic factors involved in the process of ferroptosis, such as HSP70 and HSP90 (77). These factors usually accumulate in the TME, including but not limited to inducing the maturation and activation of M1-like macrophages or DCs, to amplify the immune response and enhance the anti-tumor ability of CD8+ T cells.

Contradictorily, recent reports have shown that cancer cell ferroptosis impedes DCs-mediated anti-tumor immunity, which challenges previous studies. ML266-induced cancer cell ferroptosis can release ATP and HMGB1, as well as expose CRT. However, when bone marrow-derived dendritic cells (BMDCs) were co-cultured with ferroptotic cancer cells, it was found that the maturation of BMDCs was negatively correlated with early-stage (1-2h) ferroptotic cancer cells. Although the maturation marker molecules of BMDCs increased in the mid-stage (3-4h) and late-stage (5-8h), the maturation of BMDCs was not sufficient to induce an immune response due to the loss of antigen presentation ability after BMDCs engulf ferroptosis cell corpse. this is manifested by the decrease of antigen presentation-related gene expression and the accumulation of lipid droplets. Thus, ferroptotic cancer cells weaken the ability to activate CD8+ T cells. The inoculation of ferroptotic cancer cells cannot induce tumor immunogenic protection against newly formed tumors in vivo, regardless of the stage of cell death (early, mid, or late stage) (69). This may explain the concept that ferroptotic cancer cells are associated with poor prognosis in various cancer patients (85–87).

In a word, CD8+T cells have a higher sensitivity to ferroptosis than cancer cells, and ferroptosis cell corpses can block the activation of CD8+T cells. In addition, ferroptosis is associated with poor prognosis of various tumors (85–87). This may pose a risk to the use of ferroptosis in cancer. On the other hand, it has been shown to be effective that building polymeric drugs were specifically ingested by cancer cells to interfere with ferroptosis and boost immunity (detailed in a later chapter). Therefore, targeting cancer cells ferroptosis should be more cautious.

DCs are the main pathway for the activation of CD8+ T cells. DCs can recognize tumor-specific antigens to activate CD8+ T cells by TCR receptors (97). Therefore, DCs ferroptosis blocks the activation pathway of CD8+ T cells and downregulates anti-cancer immunity. Han et al. found that PPARG/PPARγ, a nuclear receptor involved in regulating lipid metabolism, promotes RSL3-induced ferroptosis of DCs. Genetic depletion of PPARG restores the maturation and function of DCs, activates cytotoxic T cells through signal transduction, and enhances CD8+ T cell-mediated anti-cancer immunity (88).

Tumor-associated macrophages (TAMs) play a “double-edged sword” role in the development of cancer. This may be related to TAMs subsets. Although M1-like macrophages and M2-like macrophages are TAMs subsets, M1-like macrophages showed anti-tumor immunity while M2 macrophages showed pro-tumor effect (98). Iron overload and ROS accumulation have been shown to promote the polarization of macrophages toward M1-like macrophages during ferroptosis. This may lead to partial polarization of TAMs toward M1-like macrophages and reduce the number of intra-tumoral M2-like macrophages to increase CD8+ T cell infiltration in the TME (99–103). Li et al. demonstrated that Dihydroartemisinin (DHA) increases intracellular iron levels by upregulating TFR1 and, in combination with GPX4 inhibition, initiates ferroptosis. In turn, lipid peroxidation during ferroptosis induces DNA damage response and further activates NF-kB, promoting polarization of macrophages toward the M1 phenotype (89). Similarly, Hao et al. found that inhibition of AOPCI promotes the upregulation of the multiple ferroptosis genes and enhances M2 macrophage polarization toward to M1 phenotype through the ferroptosis pathway, thereby activating CD8+ T cells and promoting anti-cancer immunity in hepatocellular carcinoma (90). Consistently, Tang et al. found that TAMs manifested xCT upregulation, ferroptosis Reduction, and M2-like polarization in hepatocellular carcinoma. Targeted xCT-mediated ferroptosis and protumoral polarization of Macrophages is effective. Inhibition or elimination of xCT combined with PD-1 can significantly reduce TAMs infiltration and M2-macrophage polarization, and enhance CD8+T cell activity (91).

Myeloid-derived suppressor cells (MDSCs) are immunosuppressive components of the TME. They can suppress the anti-cancer effects of CD8+ T cells. Promoting the polarization of MDSCs and reducing their infiltration can improve cancer immunotherapy (104). Li et al. found that TLR2 agonists promote the polarization of MDSCs and the production of ROS in hepatocellular carcinoma, which may be related to Runx1 in MDSCs. RNA sequencing of MDSCs after TLR2 agonist treatment revealed differential gene expression concentrating in the ferroptosis pathway, suggesting a link between MDSCs polarization and ferroptosis. Polarized MDSCs can increase CD8+ T cell activity and suppress tumor growth (92). Zhu et al. also found that ASAH2 is highly expressed in MDSCs and inhibits ferroptosis mediated by the p53 protein pathway. Therefore, inhibiting ASAH2 promotes ferroptosis in MDSCs, reducing their immunosuppressive ability and improving prognosis through CD8+ T cell infiltration and IFN-γ secretion (93). It is worth noting that the decrease in immunosuppressive cells is generally believed to alleviate the immunosuppressive effects of the TME. However, pathologically activated neutrophils, known as polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), have more immunosuppressive effects due to spontaneous ferroptosis mediated by low oxygen and FATP2. Although ferroptosis reduces the presence of PMN-MDSCs, the release of oxygenated lipids and prostaglandin E2 (PGE2) limits the activity of CD8+ T cells in humans and mice. In immunocompetent mice, genetic or pharmacological inhibition of ferroptosis can prevent PMN-MDSCs ferroptosis and reduce their suppressive activity, slowing tumor progression. The synergistic effect with ICIs can further enhance anti-tumor immunity, opening up new perspectives on the role of ferroptosis in immunosuppressive cells (94). Previous reports verified the equivalent identity between PMN-MDSCs and tumor-infiltrating neutrophils (TINs) (105, 106). Zhao et al. identified aconitate decarboxylase 1 (Acod1) as the most upregulated metabolic enzyme in TINs. Acod1 produces itaconate through the GM-CSF-JAK/STAT5-C/EBPb pathway to defend against ferroptosis and upholds the persistence of TINs. Acod1 ablation bolsters antitumor T cell immunity and boosts the efficacy of immune checkpoint blockade by inducing TINs ferroptosis (95).

Regulatory T cell (Treg) is another important component of the immune suppression TME, which can induce CD8+ T cell exhaustion and cause the immune escape of cancer cells (107, 108). Treg evades ferroptosis by upregulating Gpx4 in the TME. TCR/CD28 co-stimulation leads to excessive accumulation of lipid peroxides and subsequent ferroptosis in Gpx4-deficient Treg, reducing the suppressive effect of Treg in the TME. In addition, IL-1B is expressed during the ferroptosis process of GPX4-deficient Treg, promoting the activation of DCs and CD8+ T cells, and inhibiting tumor growth (96).

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are important inhibitors of T-cell responses (127, 128). Maintaining the activation of CD8+ T cells and protecting them from exhaustion and death is an effective approach in cancer immunotherapy (129, 130). Anti-CTLA-4 antibodies can attenuate the inhibition of CD8+ T cell activity, and PD-1/PD-L1 checkpoint blockade can reduce CD8+ T cell exhaustion. Therefore, blocking CTLA-4 and PD-1/PD-L1 can inhibit CD8+ T cell exhaustion and death to promote cancer cells ferroptosis, and suppress tumor growth (131, 132).

Graphene oxide (GO) is a good drug delivery carrier, and PEI-PEG is a water-soluble polymer with high-density amine and a solubilizer that can maintain stable circulation of drug molecules in the blood (133–135). Zhao et al. developed a polymeric drug molecule (GO-PEI-PEG/PD-L1 siRNA) that carries PD-L1 siRNA and can be specifically taken up by cancer tissue. The PD-L1 siRNA is released under lysosomal action, reducing the abundance of cancer cells PD-L1 and preventing PD-L1/PD-1-mediated CD8+ T cell exhaustion. Combined therapy with sorafenib significantly improved the intra-tumoral CD8+ T cell infiltration and upregulated IFN-γ expression, promoting hepatocellular carcinoma ferroptosis (110). Besides, Huang et al. designed a porous and hollow carrier using attenuated Burkholderia pseudomallei as a vehicle, loading with tumor cells lysate and adjuvant CpG to serve as a tumor vaccine(SB-LC). Tumor-associated-antigens promoted the maturation of DCs by binding to PAR1 and MR on the surface of DCs, leading to the activation of CD8+ T cells. Enhancing the anti-cancer effect of CD8+ T cells inhibits tumor growth through the ferroptosis pathway. the positive feedback loop significantly suppressed tumor growth in various mouse tumor models (111).

High ferroptosis sensitivity of immune cells limits the non-targeted application of ferroptosis inducers in cancer (44). Therefore, it is crucial to construct targeted drugs that can be specifically taken up by cancer cells and induce ferroptosis. Multiple molecules have been shown to play important roles in the process of ferroptosis, and targeting key nodes can induce ferroptosis (136, 137). “Cold tumors” are described as lacking immunogenicity and low T cell infiltration. Cancer cell ferroptosis has been shown to promote the transition from “cold tumors” to “hot tumors” and enhance adaptive immune response ( Figure 2 ) (138). One study showed that ferroptosis was a kind of ICD and promoted the maturation of BMDCs, then continuously activated the adaptive immune system and inhibited tumor growth in vivo (139). In addition, Incorporating ferroptosis and ultrasound-triggered sonodynamic therapy (SDT) synergistically elicited strong antitumor immunity by increasing the numbers of mature DCs and activated CD8+ cells and decreasing the number of MDSCs in the TME (140). Currently, preclinical studies about ferroptosis mainly focus on the construction of drug polymers that can be specifically taken up by cancer cells. These drug polymers release metal elements in cancer cells, and the transition between the reduced and oxidized states of these metal ions consumes GSH, including iron (Fe), manganese (Mn), copper (Cu), and iridium (Ir). Depletion of GSH increases lipid peroxidation, and this transition can also use H2O2 to generate highly toxic free radicals (Fenton reaction), such as 1O2, ·O2-, ·OH, HO-, amplify the ROS storm, promote lipid peroxidation and ferroptosis. In addition, drug polymers can also carry ferroptosis inducers, such as oxaliplatin prodrug, Erastin, and sorafenib, to promote cancer cell ferroptosis by inhibiting the intracellular system XC- and depleting GSH. Overall, regardless of how drug-polymer molecules induce cancer cell ferroptosis, the DAMPs released from cancer cell ferroptosis can activate APCs and CD8+ T cells to heat the TME and further enhance tumor suppression.

Based on the role of iron in ferroptosis, Ling et al. prepared a photosensitizer containing Fe2+ (IrFc1). IrFc1 can entered triple-negative breast cancer cells (TNBC) through transferrin, caused oxidative stress and lipid peroxidation when activated by light. This can lead to cancer cells ferroptosis and induce CD8+ T cell infiltration to enhance anti-tumor immunity (112). Jeong et al. created a polymer carrying Fe3+ (TA-Fe3- DOX-DSPE-PEG), which increased intracellular ROS and LPO through the Fenton reaction to mediate cell ferroptosis and enhance CD8+ cell-mediated anti-tumor immunity in cancer cells (113). Hu et al. prepared a polymer that not only carries Fe3+ but also adds oxaliplatin prodrug (PCN-Oxpt/PEG). The generation of oxaliplatin consumes GSH accompanied by the production of highly toxic -OH. Fe3+ further induces cancer cell ferroptosis through the Fenton reaction, and ferroptosis-related DAMPs increase CD8+ T cells derived IFN-γ to further enhance cell ferroptosis (114). Other metal ions can also promote ferroptosis in cancer cells through redox reactions. Li et al. prepared a polymer-drug molecule carrying erastin and Cu2+(Cu2-xSe/ZIF- 8@Era-PEG-FA). Erastin is released to inhibit SLC7A11/SLC3A2, and Cu2+ further enhances cancer cell ferroptosis through the mutual conversion between Cu+ and Cu2+. Reducing the miR301 in cancer cell-derived exosomes promotes the polarization of TAMs the M1 phenotype. These factors increase CD8+T cell infiltration to enhance tumor suppression (115). Ir is another metal element. Wang et al. synthesized a complex containing Ir3+ (Ir-pbt-Bpa). The intracellular Ir-pbt-Bpa can generate singlet oxygen and superoxide anion radicals under light irradiation, inducing ferroptosis and releasing DAMPs to induce CD8+ T cell immune responses. Even if only one site is irradiated, Tumors in the other site are significantly inhibited, indicating that Ir-pbt-Bpa can increase the number of effector memory T cells and achieve long-term anti-tumor immunity (116). Sorafenib is a drug approved by the FDA for the treatment of various advanced solid tumors. Zhou et al. prepared a cinnamaldehyde dimer carrying sorafenib (CDC@SRF), which rapidly ruptures in the cytoplasm after reaching the tumor, releasing drugs. SRF significantly enhances ferroptosis by inhibiting the system XC- and directly consuming GSH, and it also promotes DCs maturation and CD8+ T cell activation, triggering a strong immune response in vivo. After multiple doses of injection, CDC@SRF cured all mice with breast cancer (117).

Given the potent anti-tumor abilities of both CD8+ T cells and cancer cell ferroptosis, constructing nanopolymer drugs containing CD8+ T cell activators and ferroptosis targets can simultaneously activate CD8+ T cells and promote cancer cell ferroptosis, thereby amplifying the tumor therapeutic effects. ZVI-NP prepared by Hsieh et al. exhibits dual anti-tumor effects in cancer. The first mechanism involves the activation of the AMPK/mTOR signaling pathway, enhancingGSK3/-TrCP-dependent NRF2 degradation, thereby triggering ferroptosis in lung cancer cells. The second mechanism involves regulating TAMs to polarize toward the M1 phenotype and enhancing the immune activity of CD8+ T cells, fully exploiting the roles of ferroptosis and CD8+ T cells in cancer (118). Similarly, Chin et al. prepared CPBA-modified Fe3O4@Chl/Fe-CNPs to be ingested by targeting glycoprotein on bladder cancer cells, depleting GSH through the Fenton reaction, and promoting lipid peroxide-mediated ferroptosis with photodynamic therapy (PDT) and chemical dynamic therapy (CDT). The nanopolymer also reprograms the tumor immune microenvironment by reducing PD-L1, IDO-1, and TGF-β and increasing CD8+ T cells, M1-like macrophages, which unleashes the potential of transforming the tumor from cold tumor to hot tumor, greatly inhibiting tumor growth, and improving the survival rate of bladder cancer mice (119). Gold nanoparticles (AuNp) are excellent drug-delivery tools. Singh et al. applied AuNp loading miR-21-3p to directly target TXNRD1 in cancer cells, disrupting the redox balance and triggering ferroptosis, enhancing the sensitivity to anti-PD-1 antibodies. Therefore, the combination of miR-21-3p-AuNp and ICIs significantly enhances tumor suppression (120, 121). Liu et al. constructed a composite nano-platform that co-expresses six enzymes(FeCo/Fe-Co DAzyme/PL). The nano-platform can induce ROS storms, depleting GSH, inactivating GPX4, and catalyzing LOX to promote irreversible cancer cell immunogenic ferroptosis. IFN-γ from CD8+ T cells can interact with AA generated during the oxidative storm, further enhancing ferroptosis and overcoming current immunotherapy limitations (122). It has been demonstrated that hyaluronic acid (HA) molecules binding to cancer cells can guide lymphocytes to migrate deep into tumors to enhance the efficacy of immunotherapy (141). Therefore, Zhang et al. constructed a nanopolymer (Fe3+-TA@HA) that specifically targets CD44 overexpressed in squamous cell carcinoma (SCC), inducing cancer cell ferroptosis through peroxidase activity and GSH depletion. Fe3+-TA@HA also promotes the recruitment of CD4+ and CD8+ T cells in mouse tumors and suppresses tumor growth through cytokine secretion. ICIs further enhance the tumor suppression effect (123).

Some natural molecules have been shown to directly trigger ferroptosis and tumor immunity in cancer, and their combination with ICIs further enhances tumor suppression. Resveratrol (RES) can inhibit the interaction of HMMR and SLC7A11 to mediate cancer cell ferroptosis. RES also enhances the cytotoxicity of CD8+ T cells co-cultured with cancer cells and modulates the tumor immune microenvironment (124). Another natural molecule, Dihydroartemisinin (DHA), induces pancreatic cancer cell ferroptosis through upregulation of P53 and ALOX12-dependent mechanisms. DHA treatment also increases CD8+ T cells in mouse cancer tissues (125). Previous research has shown that local Mn2+ in the TME enhances cGAS-STING activity to promote the accumulation of CD8+ T cells and IFN-γ secretion, while Mn2+ entering cancer cells consumes GSH in the process of hydroxyl radical (·OH) generation during oxidative reactions, leading to ferroptosis (142). Therefore, Huang et al. prepared a nanopolymer Fe-MnO2/DHA loaded with Mn and DHA, which can simultaneously promote cancer cell ferroptosis and CD8+ T cell immunity in cancer, amplifying the anti-tumor effects and further inhibiting tumor progression (126).